Document is current

Article History

Received: 9 May 2022

Accepted: 5 September 2022

First Online: 25 October 2022

Declarations

:

: Paula R. Pohlmann reports honoraria from the FRONTIERS Editorial Board; consulting/advisory board roles for Personalized Cancer Therapy (Perthera), Immunonet BioSciences, Sirtex, Xcenda/Sirtex, CARIS, Pfizer, Heron, Puma, BOLT Therapeutics, and AbbVie; lectures for Genentech/Roche, Dava Oncology, ASCO Courses, ION Oral Oncolytics, and OncLive; research funding to her institution from Pfizer, Genentech/Roche, Pieris, Fabre-Kramer, BOLT, Byondis, and SEAGEN; and patents (United States Patent no. 9,745,377; 8,501,417; 8,486,413; 9,023,362; patent application CTC-CRC). Deena Graham reports research funding to her institute from Genentech, MedStar Health, and Napo. Tianmin Wu reports research funding to her institution from Genentech through MedStar Health. Yvonne Ottaviano reports research funding to her institution from Genentech through MedStar Health and study drug supply from Napo. Mahsa Mohebtash reports research funding to her institution from Genentech through MedStar Health and study drug supply from Napo. Shweta Kurian reports research funding to her institution from Genentech through MedStar Health and study drug supply from Napo. Donna McNamara reports research funding to her institution from Genentech through MedStar Health and study drug supply from Napo. Filipa Lynce has consulted for AstraZeneca and Daiichi Sankyo and has received research funding to her institution from AstraZeneca, CytomX, and Zentalis. Robert Warren reports research funding to his institution from Genentech. Asma Dilawari has served on the Paxman Scalp Cooling Research Advisory Committee but did not receive monetary compensation and reports research funding to her institution to conduct the study from Genentech. Suman Rao reports funding to her institution from Genentech. Candace Mainor reports research funding to her institution from Genentech through MedStar Health and study drug supply from Napo. Nicole Swanson reports research funding to her institution from Genentech (funding source) and study drug supply by Napo Pharmaceuticals. Ming Tan reports research funding to his institution from Genentech through MedStar Health. Claudine Isaacs reports consultancies for Genentech, Seattle Genetics, and PUMA. Sandra M. Swain reports grants/contracts to her institution from Breast Cancer Research Foundation, Genentech/Roche, and Kailos Genetics; consulting fees from AstraZeneca, Daiichi Sankyo, Molecular Templates, Silverback Therapeutics, Eli Lilly, Merck, Natera, Exact Sciences, Athenex, Biotheranostics, and Genentech/Roche; non-promotional speaking fees from Genentech/Roche, Daiichi Sankyo, and Beijing Medical Foundation; travel support from Genentech/Roche, Caris, and Daiichi Sankyo; serving on a data safety and monitoring board for AstraZeneca; and leadership or a fiduciary role for ASCO Conquer Cancer Foundation and The National Surgical Adjuvant Breast and Bowel Project Foundation (all outside of the submitted work). All authors received third-party medical writing support from Genentech, Inc.

: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Georgetown University Institutional Review Board on 12/09/2015 under IRB # 2015–0547.

: Written informed consent was obtained from all individual participants included in the study.

: Not Applicable.